$SNTI
Senti Biosciences, Inc. Stock $snti

$snti Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000185427023000033 Filed on March 22, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$1.286M	$59.00K	$4.286M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.802M	$10.91M	$40.85M
YoY Change	19398.71%	15832.25%	24831.64%
% of Gross Profit
Research & Development	$11.32M	$9.163M	$34.07M
YoY Change	48.86%	42.95%	55.15%
% of Gross Profit
Depreciation & Amortization	$500.0K	$450.0K	$1.398M
YoY Change	150.0%	95.65%	81.79%
% of Gross Profit
Operating Expenses	$21.12M	$20.08M	$74.92M
YoY Change	1484.38%	496.93%	1837.86%
Operating Profit	-$19.83M		-$70.63M
YoY Change	68.69%		74.63%
Interest Expense	$1.061M	$1.128M	$1.701M
YoY Change	4481.17%	23109.88%	19273.58%
% of Operating Profit
Other Income/Expense, Net	$1.112M	$678.0K	$12.42M
YoY Change	-2324.0%	-6880.0%	-183.5%
Pretax Income	-$18.72M	-$18.21M	-$58.21M
YoY Change	1329.32%	442.26%	1409.17%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$18.72M	-$18.21M	-$58.21M
YoY Change	58.55%	442.26%	1409.17%
Net Earnings / Revenue	-1455.83%	-30864.41%	-1358.14%
Basic Earnings Per Share	-$0.42		-$2.23
Diluted Earnings Per Share	-$0.42	-$0.40	-$2.23
COMMON SHARES
Basic Shares Outstanding	44.17M shares	43.86M shares	26.11M shares
Diluted Shares Outstanding	44.07M shares		26.11M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$76.11M	$98.56M	$98.56M
YoY Change	19085.26%	10982.96%	10982.96%
Cash & Equivalents	$31.60M	$57.62M	$57.62M
Short-Term Investments	$44.51M	$40.94M	$40.94M
Other Short-Term Assets	$112.0K	$101.0K	$3.390M
YoY Change	-73.98%	-63.27%	730.8%
Inventory
Prepaid Expenses	$2.202M	$1.871M
Receivables	$791.0K	$626.0K	$626.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$80.51M	$102.6M	$102.6M
YoY Change	9633.54%	70.42%	7806.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$58.99M	$56.14M	$74.55M
YoY Change	33.45%	353.88%	125.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$471.0K	$293.0K	$3.659M
YoY Change	-99.8%	66.48%	-98.41%
Total Long-Term Assets	$80.91M	$78.21M	$78.21M
YoY Change	-64.83%	114.23%	-66.02%
TOTAL ASSETS
Total Short-Term Assets	$80.51M	$102.6M	$102.6M
Total Long-Term Assets	$80.91M	$78.21M	$78.21M
Total Assets	$161.4M	$180.8M	$180.8M
YoY Change	-30.09%	86.96%	-21.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.582M	$2.267M	$2.267M
YoY Change	7757.58%	-56.29%	5636.34%
Accrued Expenses	$9.647M	$14.85M	$14.85M
YoY Change	140.07%	358.02%	358.02%
Deferred Revenue	$407.0K	$799.0K
YoY Change		-51.75%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$95.00K
YoY Change
Total Short-Term Liabilities	$12.87M	$18.05M	$18.05M
YoY Change	217.58%	24.14%	450.03%
LONG-TERM LIABILITIES
Long-Term Debt	$73.00K	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$36.15M	$35.48M	$35.48M
YoY Change	412.71%	403.21%	403.21%
Total Long-Term Liabilities	$36.22M	$35.48M	$35.48M
YoY Change	413.74%	403.21%	403.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.87M	$18.05M	$18.05M
Total Long-Term Liabilities	$36.22M	$35.48M	$35.48M
Total Liabilities	$49.09M	$53.53M	$53.53M
YoY Change	342.16%	47.36%	418.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$192.0M	-$173.3M
YoY Change		50.55%
Common Stock	$4.000K	$4.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$112.3M	$127.3M	$127.3M
YoY Change
Total Liabilities & Shareholders Equity	$161.4M	$180.8M	$180.8M
YoY Change	-30.09%	86.96%	-21.89%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$18.72M	-$18.21M	-$58.21M
YoY Change	58.55%	442.26%	1409.17%
Depreciation, Depletion And Amortization	$500.0K	$450.0K	$1.398M
YoY Change	150.0%	95.65%	81.79%
Cash From Operating Activities	-$16.30M	-$9.006M	-$34.90M
YoY Change	3209.58%	9358.1%	2955.02%
INVESTING ACTIVITIES
Capital Expenditures	$6.507M	$8.533M	$41.37M
YoY Change	-11.83%	114.4%	646.42%
Acquisitions
YoY Change
Other Investing Activities	-$2.990M	-$40.59M	-$40.59M
YoY Change			-82.35%
Cash From Investing Activities	-$9.497M	-$49.12M	-$81.96M
YoY Change	28.69%		-64.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$35.00K	876.0K	$118.6M
YoY Change	-92.31%		-48.91%
NET CHANGE
Cash From Operating Activities	-$16.30M	-9.006M	-$34.90M
Cash From Investing Activities	-$9.497M	-49.12M	-$81.96M
Cash From Financing Activities	-$35.00K	876.0K	$118.6M
Net Change In Cash	-$25.84M	-57.25M	$1.696M
YoY Change	5144.5%	60021.82%	90.71%
FREE CASH FLOW
Cash From Operating Activities	-$16.30M	-$9.006M	-$34.90M
Capital Expenditures	$6.507M	$8.533M	$41.37M
Free Cash Flow	-$22.81M	-$17.54M	-$76.27M
YoY Change	189.75%	330.38%	1040.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001854270
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays	P20D
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	74500000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44168034	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57621000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56034000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	626000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	483000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	40942000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3390000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3676000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	102579000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	60193000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3366000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	3257000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	293000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	176000	usd
CY2022Q4	us-gaap	Assets Assets	180792000	usd
CY2021Q4	us-gaap	Assets Assets	96702000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2267000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5187000	usd
CY2022Q4	snti	Early Exercise Liability Current EarlyExerciseLiabilityCurrent	135000	usd
CY2021Q4	snti	Early Exercise Liability Current EarlyExerciseLiabilityCurrent	626000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	799000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1656000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	12864000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	5331000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1988000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1743000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18053000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14543000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	176000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	53529000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	36326000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	19517990	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	19517988	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	19517988	shares
CY2022Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	usd
CY2021Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	163800000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	171833000	usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	27006600	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2972409	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2972409	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	300544000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3619000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-173286000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115076000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	127263000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-111457000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	180792000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	96702000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3286000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2291000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	74915000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	43207000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-9461000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1289000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	snti	Fair Value Adjustment Preferred Stock Tranche Liability FairValueAdjustmentPreferredStockTrancheLiability	0	usd
CY2021	snti	Fair Value Adjustment Preferred Stock Tranche Liability FairValueAdjustmentPreferredStockTrancheLiability	14742000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-32000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-120000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12419000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-14873000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-58210000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-55319000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58209000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55319000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.23
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.23
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-19.00
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-19.00
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26110785	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26110785	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2912275	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2912275	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	11536136	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	89662000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-58713000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	6000	usd
CY2021	snti	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	7981852	shares
CY2021	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	82171000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1525000	usd
CY2021	snti	Early Exercise Of Stock Options Value EarlyExerciseOfStockOptionsValue	1329000	usd
CY2021	snti	Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions	84000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2295000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	19517988	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	171833000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-111457000	usd
CY2022	snti	Temporary Equity Shares Conversion Of Convertible Securities TemporaryEquitySharesConversionOfConvertibleSecurities	19517988	shares
CY2022	snti	Temporary Equity Value Conversion Of Convertible Securities TemporaryEquityValueConversionOfConvertibleSecurities	171833000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	171835000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	111959000	usd
CY2022	snti	Adjustments To Additional Paid In Capital Contingent Consideration Liability On Closing Of The Reverse Recapitalization AdjustmentsToAdditionalPaidInCapitalContingentConsiderationLiabilityOnClosingOfTheReverseRecapitalization	9688000	usd
CY2022	snti	Stock Issued During Period Value Cancellation And Exchange Of Convertible Debt StockIssuedDuringPeriodValueCancellationAndExchangeOfConvertibleDebt	5184000	usd
CY2022	snti	Adjustments To Additional Paid In Capital Gain On Embedded Derivative AdjustmentsToAdditionalPaidInCapitalGainOnEmbeddedDerivative	-1289000	usd
CY2022	snti	Stock Issued During Period Value Purchase Agreement Fee Settled In Stock StockIssuedDuringPeriodValuePurchaseAgreementFeeSettledInStock	924000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	496000	usd
CY2022	snti	Stock Issued During Period Value Vesting Of Early Exercise Of Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions	965000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	151000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16392000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	1000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-58210000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	127263000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-58210000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-55319000	usd
CY2022	us-gaap	Depreciation Depreciation	1398000	usd
CY2021	us-gaap	Depreciation Depreciation	769000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2522000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2241000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	356000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1289000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-9461000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2022	snti	Fair Value Adjustment Preferred Stock Tranche Liability FairValueAdjustmentPreferredStockTrancheLiability	0	usd
CY2021	snti	Fair Value Adjustment Preferred Stock Tranche Liability FairValueAdjustmentPreferredStockTrancheLiability	14742000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	16392000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2295000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-12000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-22000	usd
CY2022	snti	Interest Income Accrued And Not Received InterestIncomeAccruedAndNotReceived	-12000	usd
CY2021	snti	Interest Income Accrued And Not Received InterestIncomeAccruedAndNotReceived	0	usd
CY2022	snti	Stock Issued For Purchase Agreement Fee StockIssuedForPurchaseAgreementFee	196000	usd
CY2021	snti	Stock Issued For Purchase Agreement Fee StockIssuedForPurchaseAgreementFee	0	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	8000	usd
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	131000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	395000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1302000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1642000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	186000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-617000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2055000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2574000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1033000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1832000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	14129000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1137000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34896000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34635000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	40585000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41374000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5543000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81959000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5543000	usd
CY2022	snti	Proceeds From Merger And Related Pipe Financing Net Of Transaction Costs ProceedsFromMergerAndRelatedPIPEFinancingNetOfTransactionCosts	111976000	usd
CY2021	snti	Proceeds From Merger And Related Pipe Financing Net Of Transaction Costs ProceedsFromMergerAndRelatedPIPEFinancingNetOfTransactionCosts	-17000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	521000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1500000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	728000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	151000	usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5175000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	66952000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	118551000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	68435000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1696000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	28257000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59291000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31034000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60987000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59291000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57621000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56034000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3366000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	3257000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60987000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59291000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8153000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4439000	usd
CY2022	snti	Recognition Of Preferred Stock Tranche Liability RecognitionOfPreferredStockTrancheLiability	0	usd
CY2021	snti	Recognition Of Preferred Stock Tranche Liability RecognitionOfPreferredStockTrancheLiability	33000	usd
CY2022	snti	Extinguishment Of Preferred Stock Tranche Liability ExtinguishmentOfPreferredStockTrancheLiability	0	usd
CY2021	snti	Extinguishment Of Preferred Stock Tranche Liability ExtinguishmentOfPreferredStockTrancheLiability	15210000	usd
CY2022	snti	Merger And Related Pipe Financing Costs Incurred But Not Yet Paid MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid	0	usd
CY2021	snti	Merger And Related Pipe Financing Costs Incurred But Not Yet Paid MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid	1429000	usd
CY2022	snti	Receivables In Transit From Issuance Of Common Stock Upon Exercise Of Stock Options ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions	0	usd
CY2021	snti	Receivables In Transit From Issuance Of Common Stock Upon Exercise Of Stock Options ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions	25000	usd
CY2022	snti	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	298800000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-173300000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115100000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-58200000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-55300000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	98600000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	56000000	usd
CY2022	snti	Number Of Business Activities NumberOfBusinessActivities	1	businessactivitiy
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	reportablesegment
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, the valuation of contingent earnout, the valuation of convertible notes, the valuation of common and redeemable convertible preferred stock, the valuation of preferred stock tranche liability, the valuation of stock-based compensation expense, standalone selling price (“SSP”) and the determination of the incremental borrowing rate. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash, cash equivalents, and short-term investments that are maintained in checking and money market accounts at one financial institution, which at times, may exceed federally insured limits. The Company’s short-term investments, if any, are limited to certain types of debt securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings, and places restrictions on maturities and concentration by type and issuer. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022 and 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has not experienced any credit losses in such accounts or investments.</span></div>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57621000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56034000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3366000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	3257000	usd
CY2022Q4	snti	Deferred Offering Costs Expensed DeferredOfferingCostsExpensed	0	usd
CY2021Q4	snti	Deferred Offering Costs Expensed DeferredOfferingCostsExpensed	2200000	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1400000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000	usd
CY2022Q4	snti	Cash Cash Equivalents Restricted Cash And Debt Securities Available For Sale Fair Value CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue	101929000	usd
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares ReverseRecapitalizationContingentConsiderationEquityShares	2000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Number Of Tranches ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches	2	tranche
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares Per Tranche ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche	1000000	shares
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59291000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59291000	usd
CY2022Q2	snti	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.1957
CY2022Q2	snti	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.1957
CY2022Q2	snti	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.1957
CY2022Q2	snti	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.1957
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares ReverseRecapitalizationContingentConsiderationEquityShares	2000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Number Of Tranches ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches	2	tranche
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares Per Tranche ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche	1000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays	P20D
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Consecutive Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays	P30D
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Threshold Of Years For Change Of Control ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl	P3Y
CY2022Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5060000	shares
CY2022Q2	snti	Stock Converted Reverse Recapitalization StockConvertedReverseRecapitalization	23163614	shares
CY2022Q2	snti	Early Exercised Shares Subject To Repurchase EarlyExercisedSharesSubjectToRepurchase	288807	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43368270	shares
CY2022Q2	us-gaap	Stock Issued During Period Shares Conversion Of Units StockIssuedDuringPeriodSharesConversionOfUnits	19517988	shares
CY2022Q2	snti	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	140700000	usd
CY2022Q2	snti	Reverse Recapitalization Transaction Costs ReverseRecapitalizationTransactionCosts	23500000	usd
CY2022Q2	snti	Reverse Recapitalization Transaction Costs Incurred By Company ReverseRecapitalizationTransactionCostsIncurredByCompany	4800000	usd
CY2022	snti	Reverse Recapitalization Accrued Transaction Costs ReverseRecapitalizationAccruedTransactionCosts	0	usd
CY2022Q4	snti	Cash Cash Equivalents Restricted Cash And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost	101928000	usd
CY2021	snti	Fair Value Adjustment Preferred Stock Tranche Liability FairValueAdjustmentPreferredStockTrancheLiability	14700000	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1446000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	101000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	275000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3390000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3676000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	59122000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14023000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2986000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1655000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56136000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12368000	usd
CY2022	us-gaap	Depreciation Depreciation	1400000	usd
CY2021	us-gaap	Depreciation Depreciation	800000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7342000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	605000	usd
CY2021Q4	snti	Accrued Professional Fees Other Current AccruedProfessionalFeesOtherCurrent	1950000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3743000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2665000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	29000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	111000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	12864000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	5331000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	3793000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	730000	usd
CY2022	us-gaap	Lease Cost LeaseCost	6111000	usd
CY2021	us-gaap	Lease Cost LeaseCost	4518000	usd
CY2022	snti	Operating Lease Proceeds Payments OperatingLeaseProceedsPayments	11363000	usd
CY2021	snti	Operating Lease Proceeds Payments OperatingLeaseProceedsPayments	-2669000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	231000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	10153000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y2M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.091
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.091
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6272000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7265000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7489000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7723000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5780000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	24449000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	58978000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	18543000	usd
CY2022Q4	snti	Tenant Improvement Allowance Remaining Amount TenantImprovementAllowanceRemainingAmount	3344000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	37091000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	19517990	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	19517988	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	19517988	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	171833000	usd
CY2021Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	163834000	usd
CY2022Q2	snti	Temporary Equity Conversion Ratio TemporaryEquityConversionRatio	1
CY2022Q4	snti	Number Of Votes Per Common Share NumberOfVotesPerCommonShare	1	vote
CY2022	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	27006600	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	22186271	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	23000816	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares ReverseRecapitalizationContingentConsiderationEquityShares	2000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Number Of Tranches ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches	2	tranche
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares Per Tranche ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche	1000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Earnout Period Threshold Consecutive Trading Days ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays	P30D
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Threshold Of Years For Change Of Control ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl	P3Y
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Fair Value ReverseRecapitalizationContingentConsiderationFairValue	9800000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9700000	usd
CY2022Q2	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	100000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-9500000	usd
CY2019Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	300000	usd
CY2019Q2	snti	Revenue Remaining Performance Obligation Variable Consideration Amount RevenueRemainingPerformanceObligationVariableConsiderationAmount	300000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Modification Of Contract ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract	-300000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1000000	usd
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	usd
CY2021Q4	us-gaap	Contract With Customer Asset Gross ContractWithCustomerAssetGross	0	usd
CY2022Q4	us-gaap	Contract With Customer Asset Gross ContractWithCustomerAssetGross	0	usd
CY2021Q4	us-gaap	Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Modification Of Contract ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract	-300000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2291838	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.39
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11304000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2655259	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.09
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	199839	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.49
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	555832	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.21
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4191426	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.18
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	770429	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.14
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y3M18D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.47
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.91
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	800000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8000000	usd
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	9200000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16392000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2295000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25249000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23104000	usd
CY2022Q4	snti	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	7789000	usd
CY2021Q4	snti	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	6350000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6053000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4915000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5131000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	snti	Deferred Tax Assets Share Based Compensation DeferredTaxAssetsShareBasedCompensation	683000	usd
CY2021Q4	snti	Deferred Tax Assets Share Based Compensation DeferredTaxAssetsShareBasedCompensation	28000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	756000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	738000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	259000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	45920000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35735000	usd
CY2022Q4	snti	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	3869000	usd
CY2021Q4	snti	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	5789000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	236000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3869000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6025000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42051000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29710000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12300000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	10700000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0013
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0298
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0093
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0080
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0121
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0229
CY2022	snti	Effective Income Tax Rate Reconciliation Fair Value Of Preferred Stock Tranche Liability Percent EffectiveIncomeTaxRateReconciliationFairValueOfPreferredStockTrancheLiabilityPercent	0
CY2021	snti	Effective Income Tax Rate Reconciliation Fair Value Of Preferred Stock Tranche Liability Percent EffectiveIncomeTaxRateReconciliationFairValueOfPreferredStockTrancheLiabilityPercent	-0.0560
CY2022	snti	Effective Income Tax Rate Reconciliation Fair Value Of Contingent Earnout Liability Percent EffectiveIncomeTaxRateReconciliationFairValueOfContingentEarnoutLiabilityPercent	0.0341
CY2021	snti	Effective Income Tax Rate Reconciliation Fair Value Of Contingent Earnout Liability Percent EffectiveIncomeTaxRateReconciliationFairValueOfContingentEarnoutLiabilityPercent	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2456
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1987
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-58210000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-55319000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26110785	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26110785	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2912275	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2912275	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.23
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.23
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-19.00
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-19.00
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12429123	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21832990	shares
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	usd
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	46000000	usd
CY2021Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P11Y
CY2022	snti	Collaborative Arrangement Rights And Obligations Contractual Annual Payments CollaborativeArrangementRightsAndObligationsContractualAnnualPayments	100000	usd
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares ReverseRecapitalizationContingentConsiderationEquityShares	2000000	shares
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Number Of Tranches ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches	2	tranche
CY2022Q2	snti	Reverse Recapitalization Contingent Consideration Equity Shares Per Tranche ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	snti	Number Of Seats On The Board Of Directors NumberOfSeatsOnTheBoardOfDirectors	7	tradingday
CY2021Q4	snti	Number Of Seats On The Board Of Directors NumberOfSeatsOnTheBoardOfDirectors	7	tradingday
CY2021Q4	snti	Number Of Seats On The Board Of Directors NumberOfSeatsOnTheBoardOfDirectors	7	tradingday
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	San Francisco, CA,
CY2022	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0001854270-23-000033-index-headers.html	Edgar Link	pending
0001854270-23-000033-index.html	Edgar Link	pending
0001854270-23-000033.txt	Edgar Link	pending
0001854270-23-000033-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
picture1_alamedalease.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
snti-20221231_cal.xml	Edgar Link	unprocessable
snti-20221231_lab.xml	Edgar Link	unprocessable
snti-20221231_pre.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
senti12312210kex311.htm	Edgar Link	pending
senti12312210kex312.htm	Edgar Link	pending
senti12312210kex321.htm	Edgar Link	pending
senti12312210kex322.htm	Edgar Link	pending
senti123122ex1013leaseagre.htm	Edgar Link	pending
senti123122ex1032sparkamen.htm	Edgar Link	pending
senti123122ex1033bluerocks.htm	Edgar Link	pending
senti123122ex1034jamescoll.htm	Edgar Link	pending
senti123122ex231kpmgconsent.htm	Edgar Link	pending
senti123122ex43description.htm	Edgar Link	pending
Show.js	Edgar Link	pending
snti-20221231.htm	Edgar Link	pending
snti-20221231.xsd	Edgar Link	pending
snti-20221231_g1.jpg	Edgar Link	pending
snti-20221231_g10.jpg	Edgar Link	pending
snti-20221231_g11.jpg	Edgar Link	pending
snti-20221231_g12.jpg	Edgar Link	pending
snti-20221231_g13.jpg	Edgar Link	pending
snti-20221231_g14.jpg	Edgar Link	pending
snti-20221231_g15.jpg	Edgar Link	pending
snti-20221231_g16.jpg	Edgar Link	pending
snti-20221231_g17.jpg	Edgar Link	pending
snti-20221231_g18.jpg	Edgar Link	pending
snti-20221231_g19.jpg	Edgar Link	pending
snti-20221231_g2.jpg	Edgar Link	pending
snti-20221231_g20.jpg	Edgar Link	pending
snti-20221231_g21.jpg	Edgar Link	pending
snti-20221231_g22.jpg	Edgar Link	pending
snti-20221231_g23.jpg	Edgar Link	pending
snti-20221231_g24.jpg	Edgar Link	pending
snti-20221231_g25.jpg	Edgar Link	pending
snti-20221231_g26.jpg	Edgar Link	pending
snti-20221231_g27.jpg	Edgar Link	pending
snti-20221231_g28.jpg	Edgar Link	pending
snti-20221231_g29.jpg	Edgar Link	pending
snti-20221231_g3.jpg	Edgar Link	pending
snti-20221231_g30.jpg	Edgar Link	pending
snti-20221231_g31.jpg	Edgar Link	pending
snti-20221231_g32.jpg	Edgar Link	pending
snti-20221231_g33.jpg	Edgar Link	pending
snti-20221231_g34.jpg	Edgar Link	pending
snti-20221231_g35.jpg	Edgar Link	pending
snti-20221231_g36.jpg	Edgar Link	pending
snti-20221231_g37.jpg	Edgar Link	pending
snti-20221231_g38.jpg	Edgar Link	pending
snti-20221231_g4.jpg	Edgar Link	pending
snti-20221231_g5.jpg	Edgar Link	pending
snti-20221231_g6.jpg	Edgar Link	pending
snti-20221231_g7.jpg	Edgar Link	pending
snti-20221231_g8.jpg	Edgar Link	pending
snti-20221231_g9.jpg	Edgar Link	pending
snti-20221231_def.xml	Edgar Link	unprocessable
snti-20221231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SNTI
Senti Biosciences, Inc. Stock $snti

2023 Q1 Form 10-K Financial Statement

#000185427023000033 Filed on March 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNTI Senti Biosciences, Inc. Stock $snti

2023 Q1 Form 10-K Financial Statement

#000185427023000033 Filed on March 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNTI
Senti Biosciences, Inc. Stock $snti